Literature DB >> 33876393

Management of Osteoarthritis: Expert Opinion on NSAIDs.

Alberto Magni1, Piergiuseppe Agostoni2,3, Cesare Bonezzi4, Giuseppe Massazza5,6, Paolo Menè7, Vincenzo Savarino8, Diego Fornasari9.   

Abstract

Osteoarthritis (OA) is a leading cause of disability among older adults worldwide. Treatment aims are to alleviate inflammatory pain and improve physical function through non-pharmacological and pharmacological interventions. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy. However, selection is challenged by patient age, comorbidities and polypharmacy, and by the drug's benefit/risk balance, all of which together influence the risk of cardiovascular (CV), gastrointestinal (GI) and renal adverse events (AEs). While the efficacy profile of the various NSAIDs is delineated, the differences in their safety profile are not straightforward. This narrative review provides practical indications by a multidisciplinary Italian expert panel for general practitioners and specialists managing OA patients with chronic inflammatory pain; the goal is to maximize therapy efficacy while reducing untoward effects caused by inappropriate NSAID use. The discussion on the best approach to NSAIDs spanned the following topics: (1) patient evaluation: investigate pain origin, duration and components together with possible risk factors for CV, GI and renal AEs; (2) non-pharmacological interventions: the physiatrist provides a person-centered, holistic approach accounting for all patient aspects; (3) pharmacological interventions: patient profile and drugs' pharmacological properties affect NSAID selection, which drugs to be used in combination or to be avoided, formulation and therapy duration; (4) the pharmacologist's, general practitioner's and pain therapist's points of view; (5) NSAID safety: the individual baseline risk and the drug's safety profile are major determinants of CV, GI and renal risk; consider possible drug-drug interactions; (6) periodical re-evaluation of treatment response and adherence, using scales to assess pain and function.

Entities:  

Keywords:  Chronic inflammatory pain; Clinical practice; Non-steroidal anti-inflammatory drugs; Osteoarthritis; Safety

Year:  2021        PMID: 33876393     DOI: 10.1007/s40122-021-00260-1

Source DB:  PubMed          Journal:  Pain Ther


  83 in total

1.  Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs.

Authors:  C Mel Wilcox; Byron Cryer; George Triadafilopoulos
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

Review 2.  An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Authors:  Olivier Bruyère; Germain Honvo; Nicola Veronese; Nigel K Arden; Jaime Branco; Elizabeth M Curtis; Nasser M Al-Daghri; Gabriel Herrero-Beaumont; Johanne Martel-Pelletier; Jean-Pierre Pelletier; François Rannou; René Rizzoli; Roland Roth; Daniel Uebelhart; Cyrus Cooper; Jean-Yves Reginster
Journal:  Semin Arthritis Rheum       Date:  2019-04-30       Impact factor: 5.532

3.  Managing Patient Pain: A Focus on NSAID OTC Formulations for Relief of Musculoskeletal and Other Common Sources of Pain.

Authors:  Yvonne D'Arcy; Bill McCarberg
Journal:  J Fam Pract       Date:  2018-08       Impact factor: 0.493

4.  Topical Nonsteroidal Anti-inflammatory Drugs for Acute Musculoskeletal Pain.

Authors:  Sheena Derry; Philip Wiffen; Andrew Moore
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

5.  2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Authors:  Margreet Kloppenburg; Féline Pb Kroon; Francisco J Blanco; Michael Doherty; Krysia S Dziedzic; Elsie Greibrokk; Ida K Haugen; Gabriel Herrero-Beaumont; Helgi Jonsson; Ingvild Kjeken; Emmanuel Maheu; Roberta Ramonda; Marco Jpf Ritt; Wilma Smeets; Josef S Smolen; Tanja A Stamm; Zoltan Szekanecz; Ruth Wittoek; Loreto Carmona
Journal:  Ann Rheum Dis       Date:  2018-08-28       Impact factor: 19.103

Review 6.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

7.  The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis.

Authors:  A Ariani; M Manara; A Fioravanti; F Iannone; F Salaffi; N Ughi; I Prevete; A Bortoluzzi; S Parisi; C A Scirè
Journal:  Reumatismo       Date:  2019-09-23

Review 8.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.

Authors:  Sharon L Kolasinski; Tuhina Neogi; Marc C Hochberg; Carol Oatis; Gordon Guyatt; Joel Block; Leigh Callahan; Cindy Copenhaver; Carole Dodge; David Felson; Kathleen Gellar; William F Harvey; Gillian Hawker; Edward Herzig; C Kent Kwoh; Amanda E Nelson; Jonathan Samuels; Carla Scanzello; Daniel White; Barton Wise; Roy D Altman; Dana DiRenzo; Joann Fontanarosa; Gina Giradi; Mariko Ishimori; Devyani Misra; Amit Aakash Shah; Anna K Shmagel; Louise M Thoma; Marat Turgunbaev; Amy S Turner; James Reston
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-01-06       Impact factor: 4.794

9.  Impact of potential inappropriate NSAIDs use in chronic pain.

Authors:  S Ussai; L Miceli; F E Pisa; R Bednarova; A Giordano; G Della Rocca; R Petelin
Journal:  Drug Des Devel Ther       Date:  2015-04-09       Impact factor: 4.162

10.  Italian Emergency Department Visits and Hospitalizations for Outpatients' Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study).

Authors:  Niccolò Lombardi; Giada Crescioli; Alessandra Bettiol; Marco Tuccori; Annalisa Capuano; Roberto Bonaiuti; Alessandro Mugelli; Mauro Venegoni; Giuseppe Danilo Vighi; Alfredo Vannacci
Journal:  Front Pharmacol       Date:  2020-04-06       Impact factor: 5.810

View more
  7 in total

Review 1.  Osteoarthritis complications and the recent therapeutic approaches.

Authors:  Manal A Abdel-Aziz; Helmy M S Ahmed; Aziza A El-Nekeety; Mosaad A Abdel-Wahhab
Journal:  Inflammopharmacology       Date:  2021-11-09       Impact factor: 4.473

Review 2.  Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.

Authors:  Paolo Menè; Antonella Stoppacciaro; Silvia Lai; Francescaromana Festuccia
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-05-13

3.  Highlighting the Benefits of Rehabilitation Treatments in Hip Osteoarthritis.

Authors:  Andrei-Flavius Radu; Simona Gabriela Bungau; Delia Mirela Tit; Tapan Behl; Bogdan Uivaraseanu; Mihai Florin Marcu
Journal:  Medicina (Kaunas)       Date:  2022-03-30       Impact factor: 2.948

Review 4.  The Efficacy and Safety of Zhengqing Fengtongning for Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Zeling Huang; Xiao Mao; Junming Chen; Junjun He; Shanni Shi; Miao Gui; Hongjian Gao; Zhenqiang Hong
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-20       Impact factor: 2.629

5.  Single-Dose Intra-Cartilage Delivery of Kartogenin Using a Cationic Multi-Arm Avidin Nanocarrier Suppresses Cytokine-Induced Osteoarthritis-Related Catabolism.

Authors:  Tengfei He; Irfhan Shaw; Armin Vedadghavami; Ambika G Bajpayee
Journal:  Cartilage       Date:  2022 Apr-Jun       Impact factor: 3.117

6.  New Hyaluronic Acid from Plant Origin to Improve Joint Protection-An In Vitro Study.

Authors:  Rebecca Galla; Sara Ruga; Silvio Aprile; Sara Ferrari; Arianna Brovero; Giorgio Grosa; Claudio Molinari; Francesca Uberti
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

7.  Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.

Authors:  Rehab Abdelmonem; Menna M Abdellatif; Inas Essam Ibrahim Al-Samadi; Mohamed A El-Nabarawi
Journal:  Drug Des Devel Ther       Date:  2021-10-16       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.